Shares of little known UK-based biotech firm Bicycle Therapeutics (BCYC) have fallen by roughly 30% since IPO was priced at $14 in late May. On the other hand, the stock has recently experienced multiple days of relatively higher accumulation (rising by 43% over the past week).
I had been vaguely aware of this one previously, as Nobel Prize winner Sir Greg Winter was one of the founders of the company and their novel platform technology, known as Bicycles, is purported to offer significant advantages over small molecule drugs. Additionally, I knew that one